Local S100A8 Levels Correlate With Recurrence of Experimental Autoimmune Uveitis and Promote Pathogenic T Cell Activity

Juan Yun,1 Tong Xiao,1 Lei Zhou,2–4 Roger W. Beuerman,2–4 Juanjuan Li,1,5 Yuan Zhao,6 Amir Hadayer,1 Xiaomin Zhang,7 Deming Sun,8 Henry J. Kaplan,1 and Hui Shao1

1Department of Ophthalmology and Visual Sciences, Kentucky Lions Eye Center, University of Louisville, Louisville, Kentucky, United States
2Singapore Eye Research Institute, Singapore
3Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
4Ophthalmology and Visual Sciences Academic Clinical Research Program, Duke-NUS Medical School, Singapore
5Department of Ophthalmology, The 2nd People’s Hospital of Yunnan Province, Kunming, Yunnan Province, China
6Department of Pharmaceutical Sciences, Sullivan University College of Pharmacy, Louisville, Kentucky, United States
7Department of Uveitis & Ocular Immunology, Tianjin Medical University Eye Hospital, Eye Institute & School of Optometry and Ophthalmology, Tianjin, China
8Doheny Eye Institute, Department of Ophthalmology, David Geffen School of Medicine, UCLA, Los Angeles, California, United States

Correspondence: Hui Shao, Kentucky Lions Eye Center, Department of Ophthalmology and Vision Sciences, University of Louisville, 301 E. Muhammad Ali Boulevard, Louisville, KY 40202, USA; hshao01@louisville.edu.

Submitted: October 10, 2017
Accepted: January 31, 2018


PURPOSE. To investigate the role of damage-associated molecular patterns (DAMPs) in recurrent experimental autoimmune uveitis (EAU).

METHODS. Recurrent EAU was induced in Lewis rats by interphotoreceptor retinoid-binding protein (IRBP) R16-peptide specific T cells (tEAU). Aqueous humor and serum samples were kinetically collected and DAMPs examined by quantitative proteomics, Western blot analysis, and ELISA. tEAU rats were treated with S100 inhibitor paquinimod followed by disease evaluation. The functions of T effector cells and T regulatory cells (Tregs) were compared between treated and nontreated groups. The expression of costimulatory molecules on antigen-presenting cells was examined by flow cytometry.

RESULTS. S100A8, but not high mobility group box 1 (HMGB1), in the eye was found to be correlated with intraocular inflammatory episodes. Administration of paquinimod significantly protected tEAU rats from recurrence. Treated tEAU rats had fewer R16-specific Th1 and Th17 cells, but increased numbers of Tregs. R16-specific T cells from treated tEAU rats into naive recipients prevented induction of tEAU by R16-specific T cells from nontreated tEAU rats. Moreover, APCs from treated tEAU rats expressed higher levels of a negative costimulatory molecule, CD200R, and lower levels of CD80, CD86, and MHC class II molecules compared to APCs from nontreated tEAU rats. An opposite pattern of expression of these molecules was observed on APCs incubated in vitro with recombinant S100A8.

CONCLUSIONS. Our data demonstrate a link between local expression of DAMPs and autoimmune responses, and suggest that complete S100A8/A9 blockade may be a new therapeutic target in recurrent autoimmune uveitis.

Keywords: recurrent autoimmune uveitis, immune regulation, autoreactive T cells, damage-associated molecular patterns, S100A8, HMGB1

Autoimmune (idiopathic) uveitis in humans can be acute, chronic, or recurrent, in the last of which the intraocular inflammation shows relapses and remissions that vary in frequencies and timing. The complications caused by repeated inflammation and damage inside the eye, as well as by long-term drug treatment, lead to visual impairment, which accounts for approximately 10% of legal blindness in the Western world.1 In studies using animal models of experimental autoimmune uveitis (EAU), with characteristics of the human disease, it has been found that the disease is associated with activation of autoreactive T cells.2 Adoptive transfer of activated T cells reactive with retinal antigens, such as interphotoreceptor retinoid-binding protein (IRBP), induces chronic uveitis in mice3 and recurrent uveitis in Lewis rats.4,5 In the recurrent form of tEAU, the first episode of intraocular inflammation starts at day 4 and is followed by varying numbers of remissions. Similar to the clinical signs often seen in the human disease,6 neither the duration of a single disease peak nor the interval between episodes is predictable; in addition, the right and left eyes of a single recipient often show a different rhythm of relapse. This tEAU model provides us with a useful tool for studying the regulation of pathogenic effector T cells in vivo during the course of the disease.

A number of mechanisms may contribute to the remitting-relapsing character of the disease. Inter- and intramolecular...
spreading that shifts the immunoreactivity of T effector cells has been demonstrated in equine spontaneous recurrent uveitis and recurrent autoimmune anterior uveitis in Lewis rats immunized with myelin basic protein. They have previously reported that CD4 and CD25 regulatory T cells (Tregs) make a significant contribution to controlling an ongoing inflammatory response in the eye and that dysregulation and malfunction of local Tregs is an important factor in disease recurrence, persistence, and progression. In addition, we have found that ligation of exogenous or endogenous pathogen/damage-associated molecular patterns (PAMPs/DAMPs) to pathogen recognition receptors on intraocular parenchymal cells, such as astroglial cells, can reduce the threshold at which autoreactive T cells are activated in the eye. Stimulation of astroglial cells with PAMPs/DAMPs increases the expression of MHC and costimulatory molecules and induces production of IL-6, IL-12, and IL-23, leading to the activation of Th1 and Th17 IRBP-specific T cells. One of the major endogenous DAMPs, high-mobility group box 1 (HMGB1), is immediately released as a consequence of the interaction of activated uveitogenic T cells with parenchymal cells. HMGB1 promotes CXCL12 release from parenchymal cells, and the combination of HMGB1 and CXCL12 enhances leukocyte migration. The recruitment of leukocytes, including T cells and monocytes, as well as the release of ocular antigens from damaged ocular tissues, might promote uveitogenic T cell activation, since HMGB1 antagonists or blockade of binding of CXCL12 to its receptor CXCR4 reduce ocular inflammation and suppress uveitogenic T cell proliferation and Th1 and Th17 cytokine production. These findings indicate that the innate immune response, including PAMP/DAMP release, is involved in sustaining T cell-mediated adaptive autoimmune uveitis. However, the correlation of HMGB1 with the recurrence of intraocular inflammation is unknown.

S100A8, another important DAMP member is a small-sized 10-kDa molecule and preferentially exists as a heterodimer or heterotrimer with S100A9, known as calprotectin (S100A8/10-kDa molecule and preferentially exists as a heterodimer or autoimmunity in recurrent EAU. However, the correlation of HMGB1 with DAMP release, is involved in sustaining T cell-mediated adaptive autoimmune uveitis. S100A8, another important DAMP member is a small-sized 10-kDa molecule and preferentially exists as a heterodimer or heterotrimer with S100A9, known as calprotectin (S100A8/10-kDa molecule and preferentially exists as a heterodimer or autoimmunity in recurrent EAU. However, the correlation of HMGB1 with DAMP release, is involved in sustaining T cell-mediated adaptive autoimmune uveitis. S100A8, another important DAMP member is a small-sized 10-kDa molecule and preferentially exists as a heterodimer or heterotrimer with S100A9, known as calprotectin (S100A8/10-kDa molecule and preferentially exists as a heterodimer or autoimmunity in recurrent EAU. However, the correlation of HMGB1 with DAMP release, is involved in sustaining T cell-mediated adaptive autoimmune uveitis. S100A8, another important DAMP member is a small-sized 10-kDa molecule and preferentially exists as a heterodimer or heterotrimer with S100A9, known as calprotectin (S100A8/10-kDa molecule and preferentially exists as a heterodimer or autoimmunity in recurrent EAU. However, the correlation of HMGB1 with DAMP release, is involved in sustaining T cell-mediated adaptive autoimmune uveitis. S100A8, another important DAMP member is a small-sized 10-kDa molecule and preferentially exists as a heterodimer or heterotrimer with S100A9, known as calprotectin (S100A8/10-kDa molecule and preferentially exists as a heterodimer or autoimmunity in recurrent EAU. However, the correlation of HMGB1 with DAMP release, is involved in sustaining T cell-mediated adaptive autoimmune uveitis. S100A8, another important DAMP member is a small-sized 10-kDa molecule and preferentially exists as a heterodimer or heterotrimer with S100A9, known as calprotectin (S100A8/10-kDa molecule and preferentially exists as a heterodimer or autoimmunity in recurrent EAU. However, the correlation of HMGB1 with DAMP release, is involved in sustaining T cell-mediated adaptive autoimmune uveitis. S100A8, another important DAMP member is a small-sized 10-kDa molecule and preferentially exists as a heterodimer or heterotrimer with S100A9, known as calprotectin (S100A8/10-kDa molecule and preferentially exists as a heterodimer or autoimmunity in recurrent EAU. However, the correlation of HMGB1 with DAMP release, is involved in sustaining T cell-mediated adaptive autoimmune uveitis. S100A8, another important DAMP member is a small-sized 10-kDa molecule and preferentially exists as a heterodimer or heterotrimer with S100A9, known as calprotectin (S100A8/10-kDa molecule and preferentially exists as a heterodimer or autoimmunity in recurrent EAU. However, the correlation of HMGB1 with DAMP release, is involved in sustaining T cell-mediated adaptive autoimmune uveitis. S100A8, another important DAMP member is a small-sized 10-kDa molecule and preferentially exists as a heterodimer or heterotrimer with S100A9, known as calprotectin (S100A8/10-kDa molecule and preferentially exists as a heterodimer or autoimmunity in recurrent EAU. However, the correlation of HMGB1 with DAMP release, is involved in sustaining T cell-mediated adaptive autoimmune uveitis. S100A8, another important DAMP member is a small-sized 10-kDa molecule and preferentially exists as a heterodimer or heterotrimer with S100A9, known as calprotectin (S100A8/10-kDa molecule and preferentially exists as a heterodimer or autoimmunity in recurrent EAU. However, the correlation of HMGB1 with DAMP release, is involved in sustaining T cell-mediated adaptive autoimmune uveitis. S100A8, another important DAMP member is a small-sized 10-kDa molecule and preferentially exists as a heterodimer or heterotrimer with S100A9, known as calprotectin (S100A8/10-kDa molecule and preferentially exists as a heterodimer or autoimmunity in recurrent EAU. However, the correlation of HMGB1 with DAMP release, is involved in sustaining T cell-mediated adaptive autoimmune uveitis.

Collection of AqH and Serum

AqH (20 μL/rat) was collected from both eyes by anterior chamber puncture using a 30-gauge needle under a surgical microscope and stored immediately in a −80°C freezer until use for quantitative proteomics using isobaric tags for relative and absolute quantitation (iTRAQ) and Western blot. Blood was collected from the vena cava and left 30 minutes at room temperature to clot, then was centrifuged at 9300g for 10 minutes and the serum removed and stored immediately in a −80°C freezer until use for ELISA.
Measurement of HMGB1 and S100A8 Levels in AqH by Western Blot Analysis

AqH from one R16-T cell injected rat (5 µL) was mixed with 5 µL of Laemmli reducing sample buffer and heated at 95°C for 5 minutes, then was run on SDS polyacrylamide gels. Western blotting was performed on nitrocellulose membranes (Bio-Rad, Hercules, CA, USA) as described previously.10 Using anti-S100A8 Ab (Santa Cruz, Dallas, TX, USA) and anti-HMGB1 Ab (Abcam, Cambridge, MA, USA). Rat spleen was used as a positive control for S100A8 and HMGB1.

Measurement of HMGB1 and S100A8 Levels in Serum by ELISA

Samples of serum (5 µL) were diluted 1:10 in the buffer included in the kit and added to wells precoated with HMGBl (Abcam) or S100A8 (R&D Systems, Minneapolis, MN, USA) capture Abs, then HMGBl or S100A8 levels were measured following the manufacturer's instructions.

Treatment of tEAU With an S100 Inhibitor

Naïve Lewis rats were treated with the Q compound paquinimod (ABR-215757; a gift from Active Biotech AB, Lund, Sweden), a compound that blocks binding of S100A9.23,24 The correlation between S100A8 levels in the AqH with the pathological score of uveitis was determined to be significantly different from those for controls are marked with asterisks in the figures (*P < 0.05, **P < 0.01).

Results

Association Between S100A8 Levels in the AqH and Recurrent Uveitis

To explore whether levels of DAMP family molecules correlated with recurrent episodes of EAU, we induced tEAU in Lewis rats by adoptive transfer of R16-specific T cells3 and collected AqH and sera on days 0 (naïve), 1, 4 (onset), 12 (remission), 19 (second attack), 25 (second remission), and 32 (third attack) for proteomic analysis and Western blot analysis (AqH) and ELISA (serum). We first analyzed protein profiles in the AqH samples by iTRAQ quantitative proteomics. AqH samples from six rats were pooled at each time point and assessed using the Spearman correlation coefficient by analyzing the results for duplicate samples per experiment in two independent experiments. Of the ~200 identified AqH proteins (~1% false discovery rate), 34 were found to correlate with clinical recurrence (Table) and one of these was the DAMP molecule S100A8.

The correlation between S100A8 levels in the AqH with tEAU episodes was confirmed by Western blotting (Fig. 1A). S100A8 was not detected in the naive eye and on day 1 (before the first episode of intraocular inflammation), but levels were increased during the initial attack (day 4) and during the second and third relapses (days 19 and 32) and reduced during the first and second remissions (days 12 and 25).

We have previously demonstrated that HMGB1, another important DAMP member, is an early and critical mediator in a tEAU model of chronic experimental autoimmune uveitis in mice.12 As in our previous findings in the eye in mouse tEAU,12 in the present study, HMGB1 levels were increased on day 1 after T cell transfer and remained high during the entire observation period, even in remission (Fig. 1A).

To determine whether S100A8 and HMGB1 levels in the blood correlated with tEAU score and could be used as...
TABLE The Spearman Correlation Coefficient Was Used to Determine if There Was a Nonlinear Relationship Between the Clinical Profile and Protein Relative Expression Level

<table>
<thead>
<tr>
<th>Proteins</th>
<th>E1</th>
<th>E2</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRP</td>
<td>0.954</td>
<td>0.906</td>
</tr>
<tr>
<td>PON1</td>
<td>0.823</td>
<td>0.808</td>
</tr>
<tr>
<td>CHI5L1</td>
<td>0.805</td>
<td>0.867</td>
</tr>
<tr>
<td>FN1</td>
<td>0.813</td>
<td>0.867</td>
</tr>
<tr>
<td>F3</td>
<td>0.823</td>
<td>0.906</td>
</tr>
<tr>
<td>FGG</td>
<td>0.823</td>
<td>0.709</td>
</tr>
<tr>
<td>SERPINA3K</td>
<td>0.73</td>
<td>0.867</td>
</tr>
<tr>
<td>APOE</td>
<td>0.767</td>
<td>0.63</td>
</tr>
<tr>
<td>APOA2</td>
<td>0.73</td>
<td>0.906</td>
</tr>
<tr>
<td>CFI</td>
<td>0.73</td>
<td>0.709</td>
</tr>
<tr>
<td>SERPINA3M</td>
<td>0.711</td>
<td>0.729</td>
</tr>
<tr>
<td>AFM</td>
<td>0.767</td>
<td>0.867</td>
</tr>
<tr>
<td>HP</td>
<td>0.711</td>
<td>0.591</td>
</tr>
<tr>
<td>APCS</td>
<td>0.748</td>
<td>–0.197</td>
</tr>
<tr>
<td>ITIH3</td>
<td>0.73</td>
<td>0.906</td>
</tr>
<tr>
<td>SERPINA3N</td>
<td>0.796</td>
<td>0.455</td>
</tr>
<tr>
<td>F2</td>
<td>0.783</td>
<td>0.591</td>
</tr>
<tr>
<td>CP</td>
<td>0.767</td>
<td>0.906</td>
</tr>
<tr>
<td>APOA1</td>
<td>0.636</td>
<td>0.906</td>
</tr>
<tr>
<td>C9</td>
<td>0.674</td>
<td>0.788</td>
</tr>
<tr>
<td>C6</td>
<td>0.617</td>
<td>0.906</td>
</tr>
<tr>
<td>HPX</td>
<td>0.655</td>
<td>0.867</td>
</tr>
<tr>
<td>FGB</td>
<td>0.636</td>
<td>0.808</td>
</tr>
<tr>
<td>FGA</td>
<td>0.636</td>
<td>0.906</td>
</tr>
<tr>
<td>C8B</td>
<td>0.636</td>
<td>0.788</td>
</tr>
<tr>
<td>APOH</td>
<td>0.543</td>
<td>0.65</td>
</tr>
<tr>
<td>LCN2</td>
<td>0.599</td>
<td>0.808</td>
</tr>
<tr>
<td>AMBP</td>
<td>0.543</td>
<td>0.788</td>
</tr>
<tr>
<td>SERPING1</td>
<td>0.561</td>
<td>0.749</td>
</tr>
<tr>
<td>IGH-1A</td>
<td>0.599</td>
<td>0.788</td>
</tr>
<tr>
<td>LIFR</td>
<td>0.449</td>
<td>0.906</td>
</tr>
<tr>
<td>SERPINA10</td>
<td>0.449</td>
<td>0.474</td>
</tr>
<tr>
<td>KNG1</td>
<td>0.356</td>
<td>0.788</td>
</tr>
<tr>
<td>S100A8</td>
<td>0.337</td>
<td>0.768</td>
</tr>
</tbody>
</table>

AqH samples were collected on days 0 (naïve), 1 and 4 (onset), 12 (remission), 14 (second attack), 24 (second peak), and 30 (second remission) of tEAU, and analyzed by iTRAQ quantitative proteomics. AqH samples from six eyes were pooled for each time point and assessed using the Spearman correlation coefficient by analyzing duplicate samples in two independent experiments.

biomarkers for attacks and relapses, we measured S100A8 and HMGB1 in serum collected from the same rats tested in Figure 1A and failed to detect any correlation between serum S100A8 and HMGB1 levels and tEAU (data not shown). In addition, we induced tEAU in another three rats (Fig. 1B) and measured their disease score and S100A8 and HMGB1 levels over 34 days and found no correlation between serum S100A8 levels and clinical score, while serum HMGB1 levels showed a similar pattern to those seen in the AqH in Figure 1A.

Treatment With the S100A9 Inhibitor Paquinimod Reduces Recurrence of Uveitis

To further determine the importance of S100A8/9 in the recurrence of intraocular inflammation, we treated groups of tEAU rats orally with or without paquinimod (PA), a drug that blocks the binding of S100A9,23,24 using the protocol described in the Methods section and monitored the clinical score in 6 to 21 rats from each group for 41 days, then examined the pathology (Fig. 2). Other rats from each group were used in further tests described in subsequent sections (Figs. 3–6). As judged by clinical evaluation, the PA-treated tEAU rats showed reduced inflammation during the first attack and had fewer relapses compared to the controls (Fig. 2A). Pathologic evaluation on day 41 showed infiltrating cells in the vitreous and retinal damage in the control non-PA-treated rats, but not in the PA-treated group (Fig. 2B). We also analyzed eye-infiltrating cells in PA-treated and non-PA-treated rats on day 25 by staining with a panel of antibodies specific for different leukocyte subsets, followed by flow cytometric analysis. As shown in Figure 2C, in the control group, CD4 T cells were dominant during this recurrence, while the PA-treated rats showed a profound reduction in CD4 T cells (42.4% ± 3.1 in the nontreated controls and 10.5% ± 5.9 in the PA-treated group). Percentage of NK cells (control 3.6% ± 1.3/treated 1.4% ± 1.0) and granulocytes (control 4.6% ± 2.2/treated 1.1% ± 0.8) were also significantly reduced in the eyes of PA-treated rats. However, percentages of NKT cells (control 3% ± 1.9/treated 1.9% ± 1.3) and CD11b cells (control 3.9% ± 1.3/treated 4.4% ± 3.0) were not significantly changed between treated and nontreated groups. Since total infiltrating cells were much less in treated eyes than nontreated eyes, the number of cells in each subtype in treated eyes was significantly reduced (Fig. 2D). A similar result of infiltrating leukocyte subsets was seen during the first attack on day 5 after tEAU induction (data not shown). These results suggest that S100A8/9 released by inflammatory cells might be associated with the recruitment of infiltrating cells, in particular, T cells and granulocytes.

Paquinimod Treatment Significantly Inhibits R16-Specific T Cell Responses

To further explore the role of the S100A8/9 complex in tEAU and the mechanism by which PA inhibits induction of tEAU, we measured R16-specific responses of T cells from the two groups of tEAU rats treated as in Figure 2A. As shown in Figure 3A, compared to control tEAU rats, PA-treated tEAU rats showed significantly decreased specific T cell proliferation not only on day 5 (left panel), but also on day 25 post-T cell transfer (right panel). This reduction was not due to cell death, since the day 25 PA-treated tEAU T cells contained similar numbers of apoptotic cells as control tEAU T cells when cultured in FCS-deficient medium for 24 hours (Fig. 3B) or 48 or 72 hours (data not shown).

Since both R16-specific Th1 and Th17 cells are pathogenic for tEAU induction, we examined whether PA treatment preferentially affected IFN-γ and/or IL-17 autoreactive T cells. As shown in Figure 3C, levels of IFN-γ (top panels) and IL-17 (bottom panels) released into the culture supernatants by T cells from PA-treated tEAU rats on both day 5 (left panels) and 25 (right panels) post-T cell transfer were markedly lower than those produced by T cells from control tEAU rats, indicating a long-lasting inhibitory effect of PA on pathogenic T cells (note treatment was stopped on day 10). In addition, antibody staining and flow cytometry of cells from day 25 (Fig. 3D) showed that 44.5% of T cells from control tEAU rats expressed IFN-γ and 6.5% expressed IL-17, while the corresponding figures for PA-treated tEAU rats were 7.9% and 2.3%.

R16-Specific T Cells Isolated From PA-Treated tEAU Rats Acquire Regulatory Activity

In contrast, as shown in Figure 4A, R16-specific T cells from PA-treated tEAU rats on day 5 (left panels) or day 25 (right panel) produced significant higher amounts of IL-10 in response to antigenic challenge compared to cells from control tEAU rats. Examination of the phenotype of R16-specific T cells from PA-treated tEAU rats on day 25 showed that they expressed higher...
**FIGURE 1.** Changes in levels of extracellular S100A8 and HMGB1 in the eye and blood during the course of tEAU. (A) The clinical score of tEAU was noted and AqH samples collected on days 0, 1, 4, 12, 19, 25, and 32 posttransfer for S100A8 and HMGB1 levels determined by Western blotting. Lane 1 is the positive control (rat splenocytes). (B) tEAU was induced in three rats (#1–#3) and the clinical score recorded (indicated in red) and a blood sample taken at the indicated time point, then S100A8 and HMGB1 levels in the blood of each rat were determined by ELISA.
Figure 2. Disease evaluation after treatment with or without the S100A9 inhibitor paquinimod. Groups of rats were given with plain drinking water (Ctrl) or PA-containing drinking water as described in the Methods and Materials section and were used in the studies in Figures 2 to 6. (A) Disease severity was monitored daily by slit lamp microscopy for 41 days. n = 6–21 animals per group. *P < 0.05 and **P < 0.01 compared to the Ctrl group using the Mann-Whitney U test. All values are expressed as mean ± SEM. (B) Representative pathology for A on day 41 (left two panels). H&E; original magnification, ×100, and mean ± SD of pathological score from six rats on day 41 (right panel). (C) Percentage of different subsets of infiltrating leukocytes in the eye in the two groups examined by flow cytometry on day 25. n = 3 rats in each group; all values are expressed as mean ± SEM of two different experiments. *P < 0.05 and **P < 0.01 compared to the Ctrl group. D. Summary of infiltrative cells, and subsets, from each rat of two different experiments is shown. Cells recovered from eyes of each group were counted after trypan blue staining. The number of cells was calculated based on the percentage of subsets as determined by flow cytometry.
levels of Foxp3 than responder T cells from control tEAU rats (Fig. 4B). In addition, we examined Tregs in the eyes of the control and treated groups and, as shown in Figure 4C, found that the percentage of Foxp3+ T cells in the CD4+ T cells was significantly increased in the eyes of PA-treated rats at both day 5 (left panel) and 25 (right panel). We then examined the in vivo disease-inducing ability of R16-specific T cells from PA-treated or control tEAU rats by injecting naïve Lewis rats with 5 \times 10^6 R16-specific T cells isolated on day 16 from either PA-treated or control tEAU rats or with 5 \times 10^5 cells from each group. As shown in Figure 4D, R16-specific T cells from control tEAU rats (black line) induced full disease upon transfer into naïve recipients, while those isolated from PA-treated tEAU rats (blue line) induced mild EAU without relapses. Moreover, T cells from PA-treated tEAU rats neutralized the pathogenic activity of R16-specific T cells isolated from control tEAU rats when both T cell populations were transferred into one rat (red line).

The Effect of the S100A8/9 Inhibitor Is, in Part, on APCs

To examine whether the reduced proliferation of lymphocytes was a direct effect of the S100A8/9 inhibitor on T cells or an indirect effect on T cells via APCs, we performed crossover tests in which T cell proliferation was measured using all four combinations of responder T cells and APCs isolated on day 16 from the two sets of tEAU rats. As shown in Figure 5, T cells from PA-treated tEAU rats did not respond to increasing doses of R16 in the presence of APCs from either PA-treated or control tEAU rats, whereas T cells from control tEAU rats reacted well in the presence of APCs from control tEAU rats, but not PA-treated tEAU rats, indicating that dysfunction of both T cells and APCs contributed to the T cell hyporesponsiveness in PA-treated mice.
PA-Treated APCs Show Reduced Expression of Costimulatory Molecules

To examine the phenotype of APCs from PA-treated tEAU rats, we looked at the expression of MHC class II and costimulatory molecules. As shown in Figure 6A, APCs isolated from PA-treated tEAU rats on day 16 expressed lower levels of MHC class II (difference not significant) and significantly lower levels of the costimulatory molecules CD86 and CD80 compared to the non-PA-treated tEAU rats, but significantly higher levels of CD200R.

We also examined the expression of MHC class II molecules and costimulatory molecules on APCs from tEAU that were incubated in vitro with 0, 1, or 5 μM S100A8 for 24 hours. As shown in Figure 6B, APCs exposed to S100A8 showed a dose-dependent increase in levels of MHC molecules and CD80 and CD86 and a reduction in CD200R levels.

**DISCUSSION**

There is extensive evidence that S100A8 is a very early and sensitive biomarker in experimental and clinical inflammation with various origins, such as infection, toxicity, trauma, cancer, and autoimmunity. Two decades ago, S100A8 was reported to be expressed by large ED1⁺ monocytic perivascular cells that accumulate on days 11 to 14 of aEAU induced by immunization with a retinal antigen and complete adjuvant containing H3⁷Ra mycobacterium tuberculosis (TB). A recent article compared levels of S100A8/9 molecules in the AqH of Lewis rats in two...
experimental inflammatory diseases, aEAU and primed mycobacterial uveitis (PMU; intraocular inflammation initiated by subcutaneous injection of TB H37Ra antigen followed by additional intravitreal injection of H37Ra) and found elevated S100A8 and S100A9 in both models of uveitis. In the present study, we first demonstrated that local S100A8 levels correlated with recurrent episodes of autoimmune uveitis in a rat model induced by transfer of pathogenic effector T cells without the use of infectious macrobiotics that mimics the characteristics of human recurrent uveitis. Our results suggest that S100A8 might be a critical modulator in the initiation of recurrence and serve as a warning/danger signal for a flare of inflammation. As shown in Figure 1A, S100A8 was not detected in the normal rat eye. The local increase in S100A8 might be due to a rapid influx of macrophages and other leukocytes, such as neutrophils, that express S100A8, and/or to activated tissue macrophages/microglia and dendritic cells. Since the inflammation only occurs in the eye, it is not surprising that, although systemic levels of S100A8/A9 were increased compared to the naïve control, serum levels did not correlate with uveitis activity. Our results are consistent with those in a recent clinical pilot study, which showed (1) that, in idiopathic anterior uveitis (IAU) inflammation in the iris and ciliary body without systemic involvement, serum S100A8/A9 levels were significantly higher than in healthy controls, but did not differ between IAU patients with active or inactive eye disease, whereas S100A8/A9 levels in the AqH of patients with IAU were higher than in nonuveitic controls, and (2) that, in juvenile idiopathic arthritis-associated uveitis, a form of uveitis

**Figure 5.** APCs from PA-treated rats lose the ability to activate T cells. Rats were treated as in Figure 2, then responder T cells and splenic APCs were prepared on day 16 from each group. Proliferation of all four combinations of T cells and APCs in the stimulation with increasing concentrations of R16 were measured. Baseline data for T cells without antigen stimulation were 0.091 ± 0.003 (Ctrl APC and T cells), 0.13 ± 0.005 (PA-treated APC and T cells), 0.1 ± 0.025 (Ctrl APC and PA-treated T cells), and 0.1 ± 0.025 (PA treated APC and Ctrl T cells). Representative of three separate experiments; all values are expressed as mean ± SEM. *P < 0.05 and **P < 0.01 compared to the Ctrl group.

**Figure 6.** Expression of costimulatory molecules on APCs from PA-treated tEAU rats or in vitro treated with S100A8. Rats were treated as in Figure 2, then APCs isolated on day 16 were examined for expression of MHC class II and costimulatory molecules by flow cytometry analysis. (B) APCs isolated on day 16 from control treated tEAU rats were incubated in vitro with 0, 1, or 5 μM S100A8 for 24 hours, then were examined as above. Representative of three separate experiments; all values are expressed as mean ± SEM. *P < 0.05 and **P < 0.01 compared to the Ctrl group.
with systemic involvement, S100A8/A9 levels were significantly elevated in both the AqH and serum compared to nonuveitis controls and the increase in serum S100A8/A9 levels correlated with uveitis activity.

Although extracellular S100A8/A9 levels are massively upregulated in diverse inflammatory autoimmune disorders, little is known about their roles in adaptive immune responses and their effects on T and B cells. In 2010, Loser et al. analyzed the effects of S100A8 and S100A9 in a mouse model of CD40L-induced dermatitis and showed that both are required for the development of functional autoreactive CD8+ T cells. In their study, S100A8 and S100A9 induced IL-7 production in CD8+ T cells in the animal model, and in vitro stimulation of CD8+ T-cells from human subjects with active lupus erythematosus with S100A8 and S100A9 led to upregulation of IL-7 expression. A group of anti-inflammatory drugs, quinoline-3-carboxamides (Q compounds), has been demonstrated to specifically block the binding of S100A9 to TLR4 and RAGE. Members of this drug family have shown proof-of-concept in clinical trials for the treatment of autoimmune diseases, such as multiple sclerosis, systemic lupus erythematosus, and Crohn’s disease. PA was found to inhibit the priming of proinflammatory effector CD4+ T cells in experimental autoimmune encephalitis and selectively inhibit recruitment of Ly6C+ inflammatory monocytes and eosinophils during sterile peritoneal inflammation elicited by infecting necrotic tumor cells in B6 mice. We therefore used PA to explore the role of the extracellular S100A8/A9 in adaptive immune responses and their effects on T cells in tEAU. Our data showed that oral administration of PA significantly protected rats from recurrences. The mechanisms by which PA reduced intraocular inflammation were (1) inhibition of recruitment of inflammatory cells into the eye (Fig. 2) and (2) a reduction in the numbers of R16-specific Th17 and Th1 cells and an increase in the numbers and functions of Tregs (Figs. 3, 4). Coinjection of PA-treated R16-specific T cells into naive recipients prevented induction of tEAU by pathogenic R16-T cells, indicating an inhibitory function of Tregs. The results that the PA-treated T cells have inhibitory effects on T effector cells (Fig. 4) could be explained by increases in the number and function of Tregs, which might be in part converted from PA-treated T effector cells. By performing cross-proliferation tests in which T cell proliferation was measured using all combinations of responding T cells and APCs isolated from tEAU rats with or without treatment with PA, we found that increased Tregs in PA-treated tEAU rats might be due, in part, to an effect on APCs, which expressed reduced levels of CD80, CD86, and MHC class II antigen and increased levels of CD200R (Fig. 6A). CD200R functions as a coinhibitory receptor that, upon interaction with CD200, hinders myeloid cell function. In addition, CD200 has also been demonstrated to downmodulate T and NK cell functions. Whether increased expression of CD200R in APCs leads to reduced T effectors and increased Tregs requires further investigation. An opposite effect on the expression of these molecules was seen on APCs incubated in vitro with recombinant S100A8 (Fig. 6B). A previous study using PA in experimental autoimmune encephalomyelitis showed that PA ameliorates the disease by reducing effector T cell priming when given before disease induction by antigen immunization, and, on prolonged treatment, by selectively decreasing distinct subpopulations of splenic CD11b+ myeloid cells. Our results showing that PA treatment in tEAU increases Tregs, which might be in part converted from T effector cells demonstrates a new mechanism for the effect of PA in T cell-mediated autoimmune diseases.

In summary, our data show that the S100A8/A9 molecules play a critical role during recurrent uveitis, exerting and amplifying autocrine and paracrine proinflammatory effects on APCs and T cells, and reducing numbers and function of Treg cells that promote inflammatory remission. In addition, S100A8 increases the expression of positive costimulatory molecules and reduces the expression of a negative costimulatory molecule. Our data demonstrate a link between local expression of DAMP molecules and autoimmune responses and suggest that complete S100A8/A9 blockade may be a new therapeutic target in recurrent uveitis.

Acknowledgments

The authors thank the editorial assistance of Tom Barkas. Supported in part by grant EY024051 from National Institutes of Health, Research to Prevent Blindness (RPB), the Commonwealth of Kentucky Research Challenge Trust Fund, and Kentucky Engineering and Science Foundation.

Disclosure: J. Yun, None; T. Xiao, None; L. Zhou, None; R.W. Beuerman, None; J. Li, None; Y. Zhao, None; A. Hadayer, None; X. Zhang, None; D. Sun, None; H.J. Kaplan, None; H. Shao, None

References


15. Kerkhoff C, Klempt M, Sorg C. Novel insights into structure and function of MRP8 (S100A8) and MRP14 (S100A9). Biochimica et Biophysica Acta. 1998;1448:200–211.

16. Leach ST, Yang Z, Messina I, et al. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol. 2007;42:1321–1331.


